Theravance Biopharma Faces Challenges as CYPRESS Study Falls Short of Goals

Theravance Biopharma, Inc. published key findings from its Phase 3 CYPRESS study, which aimed to assess the efficacy of ampreloxetine in treating symptomatic neurogenic orthostatic hypotension, specifically for patients with multiple system atrophy (MSA). Unfortunately, the results did not meet the primary endpoint, the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, disappointing both investors and the patient community desperately seeking new treatment options.

The company has been navigating a challenging landscape, and this setback has led to significant adjustments in its strategy. Together with these disappointing findings, Theravance's Board of Directors announced that it would be accelerating its strategic review process to explore alternatives that could enhance shareholder value. The Strategic Review Committee, established in 2024, has been actively collaborating with Lazard, an independent financial advisor, to identify viable opportunities for value maximization. Among the potential actions, a complete sale of the company is on the table, although no definitive agreements or transactions have been announced yet.

In light of the study outcomes, Theravance is shifting focus towards cutting costs within its operations. The company has initiated a restructuring plan that aims to reduce operating expenses by roughly 60%, which equates to approximately $70 million. This change is expected to allow the company to generate between $60 to $70 million in annual cash flow beginning in the third quarter of 2026.

One of the strategic shifts involves winding down the development function associated with ampreloxetine, which is seen as a necessary step to streamline operations and reallocate resources towards products that are producing cash flow. Currently, the company is expecting $326.5 million in cash by the end of Q4 2025, with a further increase anticipated to approximately $400 million by the end of Q1 2026, bolstered by cash milestones from YUPELRI and TRELEGY products.

The performance of YUPELRI, Theravance's branded product for chronic obstructive pulmonary disease (COPD), has shown resilience despite the setback from the CYPRESS study. In FY 2025, YUPELRI's net sales reached $266.6 million, representing a 12% year-on-year growth. This growth has contributed to the ongoing financial stability of the company, allowing it to maintain a reliable cash flow. The company is now poised to leverage YUPELRI's strong market position while assessing future opportunities.

CEO Rick E Winningham expressed regret over the CYPRESS study results, particularly for the patients who had been eagerly anticipating new treatment options. He has also emphasized gratitude toward those who contributed to the ampreloxetine program, acknowledging the hard work and dedication of both employees and external stakeholders.

As the company moves forward, it is also undertaking a comprehensive analysis of the CYPRESS dataset to evaluate whether there are any aspects that merit further regulatory discussion. The outcomes of this analysis will contribute to the broader decision-making process regarding the potential wind-down of the ampreloxetine program.

Organizations often face pivotal moments that require decisive actions to ensure their future success. In Theravance's case, the CYPRESS study results serve as a catalyst for necessary restructuring actions, refocusing on profitable products while maintaining a keen eye on shareholder value. In the competitive pharmaceutical industry, adaptability and strategic foresight will be paramount for Theravance Biopharma as it navigates this complex landscape. The coming months will be critical as the company reassesses its strategies for sustained growth and focus on shareholder returns.